Evaluate Safety of Adipose Derived Mesenchymal Stem Cell Transplantation for Type 1 Diabetes Treatment

Inclusion Criteria: * Patient diagnosed T1D (according to the instructions of the Ministry of Health No: 5481/QD-BYT dated December 30, 2020) * Aged from 5 years and over. * The time from the diagnosis of type 1 diabetes to enrollment ≤ 12 months. * Blood testing conducted at the time of diagnosis: * Fasting blood glucose ≥ 7 mmol / L, * HbA1C ≥ 6.5%. * Have at least one antibodies associated with T1D such as ICA; GAD; ZnT8 or IAA. * At the time of screening at Vinmec for study enrollment, patients are actively managing their blood glucose levels with insulin. * The patient does not have other serious acute illness requiring treatment * The patient agrees to use stem cell transplant for treatment * The patient's parent (parent or legal guardian) can read, write, understand the ICF form and agree to sign a consent to participate in the study. Exclusion Criteria: * Having evidence related to renal dysfunction: creatinine \> 1.5 mg/dl or (\>133 mmol/L) for boys, creatinine \> 1.4 mg/dl or (\>124 mmol/L) for girls * In case of kidney failure. Proteinuria within the range of nephrotic syndrome (\>3.5 g/day or ratio of protein/creatinine in urine \>2.7) * In case of kidney failure * Having severe infection or infected with hepatitis B virus, hepatitis C virus, HIV virus, or tuberculosis * Cardiovascular disease, respiratory disease (pulmonary, fibrosis, chronic respiratory failure), liver disease, cancer or neurological disease * Blood clotting disorders (INR\> 1,5, PTT\> 40, PT\> 15). * Taking any anticoagulant * Taking systemic steroids * Participate in another clinical study involving experimenting drugs and/or medical equipment * History of allergic reaction to anesthetic agents and/or antibiotics